CN101244047B - Application of octacosanol in preparing medicament for preventing and controlling altitude erythrocytosis - Google Patents
Application of octacosanol in preparing medicament for preventing and controlling altitude erythrocytosis Download PDFInfo
- Publication number
- CN101244047B CN101244047B CN2008100694553A CN200810069455A CN101244047B CN 101244047 B CN101244047 B CN 101244047B CN 2008100694553 A CN2008100694553 A CN 2008100694553A CN 200810069455 A CN200810069455 A CN 200810069455A CN 101244047 B CN101244047 B CN 101244047B
- Authority
- CN
- China
- Prior art keywords
- octacosanol
- application
- medicine
- erythrocytosis
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to an application of octacosanol in the preparation of medicine used for preventing altitude erythrocytosis, which is characterized in that: the extracted octacosanol with the purity of 98% and the disintegrant of carboxymethyl starch are mixed together, and then are taken into a capsule, wherein, in each capsule, the octacosanol is 10mg and the disintegrant is 0.3mg. The application has the advantages of effectively preventing increase of erythrocyte caused by long-term chronic anoxia, enhancing anoxic tolerance of organism and improving microcirculation.
Description
Technical field
The present invention relates to the medicinal application of existing octacosanol, be specifically related to octacosanol and prevent and treat application in the high altitude erythrocytosis medicine in preparation.
Background technology
Long-term chronic hypoxia can cause erythrocytosis, and this helps improving the oxygen carrying capacity of blood flow, improves the tissue oxygen confession, is the effective compensatory response of organism adaptation environment of low oxygen plateau.But groups of people's erythrocyte overcompensation hypertrophy, hemoglobin concentration surpasses 200g/L, is called high altitude erythrocytosis.Because whole blood volume definitely increases, add the anoxia red cell deformability and reduce, make blood viscosity increase, resistance of blood flow strengthens, and flows slowly, and high blood coagulation state further increases the weight of histoorgan congestion, anoxia, forms a kind of vicious cycle.Clinical manifestation is many organs hypoxic damage, gets involved with the more internal organs of oxygen consumption such as brain, the heart, lung, liver etc. especially and attaches most importance to.The high altitude erythrocytosis sickness rate is 2.43% at the above plateau of height above sea level 3000m sickness rate, and increases the morbidity showed increased with height above sea level, is the commonly encountered diseases of highlands health risk, does not still have satisfied Therapeutic Method and medicine so far.
Octacosanol (1-octacosanol) is naturally occurring high fatty alcohol, be distributed widely in the lipid of the epidermis of animal and internal organs, the excretory waxiness of insecticide and plant roots, stem, leaf, shell, seed core, wide material sources, have no side effect, as natural health food additive and the natural good medicine of wide spectrum, fields such as sports drink, natural health-care products, medicine and cosmetics have been used at present.Granted publication number is called the Chinese invention patent of " preparation method of the pure and mild triacontanol of a kind of Testa oryzae active substance octacosane " for CN1257142C, name, disclosing with chaff wax is raw material, through making with extra care of chaff wax, adopt ultrasound wave hydrolysis chaff wax, the extraction of aliphatic alcohol, molecular distillation technique separates the method for octacosanol, triacontanol, prepare purity greater than 80% product, and iodine value is low, heavy metal and content of microorganisms all meet the food additive requirement, for condition has been created in the development and use of higher alcohols from now on.Studies show that; octacosanol has different physiological roles; comprise resisting kinetic fatigue; stamina intensifying, energy and muscle power; blood fat reducing, angiocardiopathy preventing, antiplatelet aggregation, cytoprotection and heart and cerebrum ischemia had protective effect etc.; the prompting octacosanol may become a kind of effective anoxia-resistant food, but the relevant effect that it prevents and treats high altitude erythrocytosis there is no report in the home and abroad so far.
Summary of the invention
The new purposes that the purpose of this invention is to provide a kind of octacosanol, being octacosanol prevents and treats application in the high altitude erythrocytosis medicine in preparation, it can effectively reduce erythrocytosis due to the long-term chronic hypoxia, and microcirculation improvement is taken for a long time and had no side effect.
Octacosanol of the present invention is prevented and treated application in the high altitude erythrocytosis medicine in preparation, it is characterized in that: the octacosanol that extracts is mixed with disintegrating agent, incapsulate.
Described octacosanol is prevented and treated application in the high altitude erythrocytosis medicine in preparation, and it is characterized in that: the purity of octacosanol is more than 98%.
Described octacosanol is prevented and treated application in the high altitude erythrocytosis medicine in preparation, it is characterized in that: contain octacosanol 10mg, disintegrating agent 0.3mg in every capsules.
Described octacosanol is prevented and treated application in the high altitude erythrocytosis medicine in preparation, and it is characterized in that: described disintegrating agent is a carboxymethyl starch, has super-strong moisture absorbing, suction back rapid expanding.The present invention adds carboxymethyl starch can imbibition in intestinal, helps rapid release to go out ingredient.
Human experimentation proves: 1 year male of height above sea level 3660m plateau inhabitation, and it is oral to give octacosanol, and each 1, every day 2 times.Blood hemoglobin concentration significantly reduces after January, and the matched group blood hemoglobin concentration that gives placebo does not have remarkable change.
Animal experiment proves: anoxia+octacosanol is irritated stomach group rat packed cell volume (HCT) and significantly is lower than simple Hypoxic Rats (P＜0.05), mean corpuscular hemoglobin concentration (MCHC) (MCHC) highly significant is higher than simple Hypoxic Rats (P＜0.01), and mean corpuscular volume (MCV) (MCV), mean corpuscular hemoglobin (MCH), Erythrocyte hemoglobin distribution width standard deviation (RDW-SD), the Erythrocyte hemoglobin distribution width coefficient of variation (RDW-CV) highly significant are lower than simple Hypoxic Rats (P＜0.01); Anoxia+octacosanol is irritated stomach group rat erythrocyte fragility and significantly is lower than simple Hypoxic Rats (P＜0.05).
The effect that the present invention is useful: octacosanol can effectively be prevented and treated erythrocytosis due to the long-term chronic hypoxia; Octacosanol can effectively improve body anoxia toleration; Octacosanol has the effect of microcirculation improvement.
The specific embodiment
Octacosanol of the present invention is prevented and treated application in the high altitude erythrocytosis medicine in preparation, it is characterized in that: purity is formed sediment with disintegrating agent-carboxymethyl at the octacosanol more than 98% mix, incapsulate; Contain octacosanol 10mg, disintegrating agent 0.3mg in every capsules.
Animal and human's body process of the test and result are as follows:
(1) octacosanol is to the influence of Chronic Hypoxic Rats routine blood test
The male adult Sprague Dawley rat of cleaning level places in the simulation height above sea level 5000m toy decompression chamber and raises, and decompression time is 23h/d.Behind the 30d rat is anaesthetized with urethane, the common carotid artery intubate is got blood, detects the routine blood test index.Found that, anoxia+octacosanol is irritated stomach group rat packed cell volume (HCT) and significantly is lower than simple Hypoxic Rats (P＜0.05), mean corpuscular hemoglobin concentration (MCHC) (MCHC) highly significant is higher than simple Hypoxic Rats (P＜0.01), and mean corpuscular volume (MCV) (MCV), mean corpuscular hemoglobin (MCH), Erythrocyte hemoglobin distribution width standard deviation (RDW-SD), the Erythrocyte hemoglobin distribution width coefficient of variation (RDW-CV) highly significant are lower than simple Hypoxic Rats (P＜0.01) (table 1).
Table 1 octacosanol to the influence of Chronic Hypoxic Rats routine blood test (
N=11)
* P＜0.05vs. matched group * * P＜0.01vs matched group
(2) octacosanol is to the influence of Chronic Hypoxic Rats erythrocyte fragility
Detect the rat erythrocyte fragility with the osmotic pressure experiment, found that anoxia+octacosanol filling stomach group rat erythrocyte fragility significantly is lower than simple Hypoxic Rats (P＜0.05) (table 2).
Table 2 octacosanol is to the influence of Chronic Hypoxic Rats erythrocyte fragility
* P＜0.05vs. matched group
(3) octacosanol is to living in the influence of height above sea level 3660m plateau male's hemoglobin concentration for long
The male of Han nationality who lived 1 year on height above sea level 3700m plateau is divided into octacosanol group and matched group at random, and it is oral that the octacosanol group gives octacosanol 10mg continuously, and 2/d takes January continuously; Matched group is taken placebo simultaneously.Extracting vein blood after the last administration adopts the high methods for iron of cyaniding to detect hemoglobin concentration.Found that, give octacosanol after oral January blood hemoglobin concentration significantly reduce (P＜0.05), and the matched group blood hemoglobin concentration that gives placebo does not have remarkable change (P＞0.05) (table 3).
Table 3 octacosanol is to living in the influence of height above sea level 3660m plateau male's hemoglobin concentration for long
Before * P＜0.01vs. takes medicine
Claims (4)
1. octacosanol is prevented and treated application in the high altitude erythrocytosis medicine in preparation, it is characterized in that: the octacosanol that extracts is mixed with disintegrating agent, incapsulate.
2. octacosanol according to claim 1 is prevented and treated application in the high altitude erythrocytosis medicine in preparation, and it is characterized in that: the purity of octacosanol is more than 98%.
3. octacosanol according to claim 1 is prevented and treated application in the high altitude erythrocytosis medicine in preparation, and it is characterized in that: every capsules is made up of the pure and mild 0.3mg disintegrating agent of 10mg octacosane.
4. octacosanol according to claim 1 is prevented and treated application in the high altitude erythrocytosis medicine in preparation, and it is characterized in that: described disintegrating agent is a carboxymethyl starch.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008100694553A CN101244047B (en) | 2008-03-11 | 2008-03-11 | Application of octacosanol in preparing medicament for preventing and controlling altitude erythrocytosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008100694553A CN101244047B (en) | 2008-03-11 | 2008-03-11 | Application of octacosanol in preparing medicament for preventing and controlling altitude erythrocytosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101244047A CN101244047A (en) | 2008-08-20 |
| CN101244047B true CN101244047B (en) | 2010-09-08 |
Family
ID=39944871
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2008100694553A Active CN101244047B (en) | 2008-03-11 | 2008-03-11 | Application of octacosanol in preparing medicament for preventing and controlling altitude erythrocytosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101244047B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110101689A (en) * | 2019-05-24 | 2019-08-09 | 江西省科学院生物资源研究所 | N-octacosanol is preparing the application in preventing liver injury drug |
| CN114209834B (en) * | 2021-05-07 | 2023-06-23 | 中国人民解放军军事科学院军事医学研究院 | Use of MCUR1 as biomarker for altitude erythrocytosis and method for screening drugs |
-
2008
- 2008-03-11 CN CN2008100694553A patent/CN101244047B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN101244047A (en) | 2008-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102960808B (en) | Alcohol-alleviating anti-fatigue beverage | |
| KR101090284B1 (en) | Tonic comprising red ginseng and deer antlers extracts and manufacturing method thereof | |
| CN103725469B (en) | A kind of health dry red winew | |
| CN101284122A (en) | Soft capsules for resisting the climate sickness | |
| CN103445115B (en) | Kudzu root health-care nutrient powder with function of improving alimentary anemia | |
| CN102697035A (en) | Cordyceps anti-aging pellet | |
| KR20170060307A (en) | Oriental herb beverage composition for pet and method thereof | |
| CN103750094A (en) | Male hachinoko health-care paste and preparation method thereof | |
| CN102526346B (en) | Health-care pharmaceutical formulation with immunity-enhancing and senility-delaying functions | |
| CN101401651A (en) | Culinary Chinese medicinal composition | |
| CN101244047B (en) | Application of octacosanol in preparing medicament for preventing and controlling altitude erythrocytosis | |
| CN101721403A (en) | Application of fucoxanthin in aspect of losing weight | |
| CN104799289A (en) | Compound nutritious food with antineoplastic and immunity enhancement functions and production method for compound nutritious food antineoplastic and immunity enhancement functions | |
| CN105477100A (en) | Lucid ganoderma spore oil compound health care spray and preparation method | |
| CN102188515A (en) | Purpose of the plant Sibiraea angustata | |
| CN102302114A (en) | Pollen-containing health-care food and preparation method thereof | |
| CN105030858A (en) | Cynomorium songaricum healthcare tablet and preparation method thereof | |
| KR101713115B1 (en) | Cosmetic composition containing the fermented extract of allium monanthum, allium scorodorpasum, allium tuberosum, allium fistulosum and scilla scilloides | |
| CN104055115B (en) | A kind of health products containing agate coffee, the stem of noble dendrobium and Panax Japonicus Var. Major and preparation method thereof | |
| CN105125738A (en) | Traditional Chinese medicinal composition as well as preparation method and application thereof | |
| CN108888750A (en) | Cordyceps sinensis pueraria lobata compound with function of blood sugar reduction | |
| CN103536659A (en) | Traditional Chinese medicine for adjusting dysfunction of qi and blood as well as preparation method thereof | |
| CN108096570A (en) | Cordyceps sinensis protein peptides piece with toxin expelling weight losing function | |
| CN107467324A (en) | A kind of active component containing American cockroach has the coffee of anti-inflammation detumescence effect | |
| CN107233490A (en) | A kind of maca composition of supplementing qi and nourishing yin beautifying face and moistering lotion |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |